V Scholar Plus Award – extended funding for exceptional V Scholars
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults. The majority of patients diagnosed are over the age of sixty and individuals in this age range experience poor response to treatment and worse clinical outcomes compared to younger patients. Despite advances in the field, clinical outcomes for AML patients over the age of sixty remain poor. To improve upon current treatment options for AML patients over the age of sixty, it is essential to better understand the mechanisms that drive the disease in these patients. The project proposed utilized data generated from AML patients older than 60 to identify RBM47 as a potential biomarker and driver of the disease. We will utilize data from another set of patients to confirm the association between the level of RBM47 in AML cells and clinical outcomes in these patients. Furthermore, in order to identify how RBM47 may contribute to the disease, we will determine what aspect(s) of AML biology RBM47 may regulate. Collectively, these findings will contribute to a body of knowledge for a long-term goal of identifying potential targetable mechanisms of disease that could be used to develop new and more effective treatments for AML patients over the age of sixty.